Skip to content

Africa COVID-19 Vaccine Hesitancy

Africa COVID-19 Vaccine Hesitancy: a Multi-country Cross-sectional Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04912284
Acronym
ACHES
Enrollment
4977
Registered
2021-06-03
Start date
2021-05-05
Completion date
2021-06-06
Last updated
2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

Vaccine hesitancy, Vaccines, West Africa

Brief summary

Vaccine hesitancy is defined by the WHO's Strategic Advisory Group of Experts on Immunization as a 'delay in acceptance or refusal of vaccination despite availability of vaccination services'. This varies in form and intensity based on when and where it occurs and what vaccine is involved. Several prophylactic vaccines against COVID-19 are currently available. As the world is beginning the roll-out the first approved vaccines, little is known about people's potential acceptance of a COVID-19 vaccine in most of the African countries. ACHES (African COVID -19Vaccine Hesitancy) is an observational study aimed at measuring COVID-19 vaccine hesitancy in five west African countries and exploring causes behind the hesitancy with the main objective of informing guidelines for the proficient roll-out of the vaccines in the region.

Detailed description

Coronavirus disease 2019 (COVID-19) was declared a Public Health Emergency of International Concern by the World Health Organization (WHO) in March 2020. Although African countries seem to have weathered the pandemic relatively well so far, with fewer than one confirmed case for every thousand people and around 50,000 death, the African continent has now officially over two million- COVID-19- case threshold. In 2015, WHO's Strategic Advisory Group of Experts on Immunization defined vaccine hesitancy as a 'delay in acceptance or refusal of vaccination despite availability of vaccination services', which can vary in form and intensity based on when and where it occurs and what vaccine is involved. Several prophylactic vaccines against COVID-19 are currently in development. As the world is beginning the roll-out the first approved vaccines, little is known about people's potential acceptance of a COVID-19 vaccine in most of the African countries. A recent study published in Nature provides results on the acceptability of vaccines in 19 of the 35 hardest hit countries worldwide. South Africa was the only African country included in the survey. An additional survey conducted in 15 African countries between August and December 2020, reveals that the majority of Africans would take a safe and effective vaccine. Nevertheless, vaccine hesitancy towards COVID-19 vaccines evolves over-time. In this view, it is crucial to investigate in depth barriers and facilitators influencing vaccine hesitancy/acceptability within African population. During the last decade several initiatives have emerged that aim at improving vaccine coverage and acceptability across the African continent. A noteworthy example is the Francophone African Civil Society Organizations' Platform for Strengthening Health Systems and Immunization, which has been since 2015 supported by GAVI (Global Alliance for Vaccines and Immunisation). OAFRESS encourages activities among francophone African members, with the primary objective of reinforcing capacities and coordinating strategies among these countries. The last West African Ebola epidemic demonstrated the importance of engaging communities in order to promote vaccine acceptability. The three most hit countries, Guinea, Sierra Leone, and Liberia, worked together and invested in research and campaigns to identify and address barriers and facilitators of vaccine acceptance, which informed both clinical vaccine studies and roll-out strategies. In order to promote the equitable and prompt roll-out of the COVID-19 vaccine worldwide, as the COVAX initiative strives for, factors influencing vaccine hesitancy in low and middle-income countries need to be investigated more thoroughly. The request for a first roll-out of the vaccines in eligible countries was to be submitted by December 7, 2020. Many of the eligible African countries have placed the order to receive the vaccines, which are already being deployed within these first months of 2021. Country and population preparedness are crucial to making the roll-out a success. 2\. Study Objectives 2.1 Overall objective To investigate COVID-19 vaccine hesitancy among five African countries to inform effective context-specific public health strategies for roll-out of vaccination. 2.2 Primary objectives • To describe and compare levels of COVID-19 vaccine hesitancy among the general population and health care workers in rural and urban settings across African countries 2.3 Secondary objectives • To explore factors influencing COVID-19 vaccination hesitancy among the general population and health care workers in urban and rural Africa 3\. Methodology 3.1 Study design A cross-sectional survey will be conducted in five African countries. A core study will be implemented in five countries, other countries will enter the study as budget will become available. Study participants will be selected among the general population aged older than 18 and health care workers. Sample sizes have been calculated separately for these two groups.

Interventions

None listed

Sponsors

Institut de Recherche en Sciences de la Sante, Burkina Faso
CollaboratorOTHER_GOV
University of Bamako
CollaboratorOTHER
Cheikh Anta Diop University, Senegal
CollaboratorOTHER
University of Sierra Leone
CollaboratorOTHER
Gamal Abdel Nasser University of Conakry
CollaboratorOTHER
Bernhard Nocht Institute for Tropical Medicine
Lead SponsorOTHER_GOV

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

General population * Be at least 18 years of age, be willing and able to provide written informed consent AND Health professionals * To be health professionals working in health care institutions at all levels of care for the Ministry of Health (MoH) * freely consent to participate in the study

Exclusion criteria

* All minors (\<18) * All individuals who do not meet the inclusion criteria listed above and those who are not willing to give written informed consent for participation in this research In Senegal * All those already vaccinated or being offered a vaccination for COVID-19 and refused and/or delayed the vaccination

Design outcomes

Primary

MeasureTime frameDescription
Frequency of vaccine hesitancy1 monthTo describe and compare levels of COVID-19 vaccine hesitancy among the general population and health care workers in rural and urban settings across different African countries

Secondary

MeasureTime frameDescription
Factors influencing vaccine hesitancy1 monthTo explore factors influencing COVID-19 vaccination hesitancy among the general population and health care workers in urban and rural Africa

Countries

Burkina Faso, Guinea, Mali, Senegal, Sierra Leone

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026